Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Bradley T, Zuquello RA, Aguirre LE et al (2020) Spontaneous remission of acute myeloid leukemia with NF1 alteration. Leuk Res Rep 13:100204PubMedPubMedCentral
2.
Armstrong C, Au WY, Ma E, Wong S, Orfali N (2023) Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma. Ann Hematol 102(5):1271–1274CrossRefPubMed
3.
Kleef R, Jonas WB, Knogler W, Stenzinger W (2001) Fever, cancer incidence and spontaneous remissions. NeuroImmunoModulation 9(2):55–64CrossRefPubMed
4.
Helbig D, Quesada AE, Xiao W, Roshal M, Tallman MS, Knorr DA (2020) Spontaneous remission in a patient with acute myeloid leukemia leading to undetectable minimal residual disease. J Hematol 9(1–2):18–22CrossRefPubMedPubMedCentral
5.
Grunwald VV, Hentrich M, Schiel X et al (2019) Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis. Blood Adv 3(18):2696–2699CrossRefPubMedPubMedCentral
Metadata
Title
Transient Spontaneous Remission of Acute Myeloid Leukemia with Mutated RUNX1: A Rare Report
Authors
Xue Wu
Jingyuan Zhao
Yingying Chen
Zhihua Zhang
Xinhong Yang
Publication date
22-03-2024
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01758-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits